Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Haruhiko Yanagisawa"'
Autor:
Takanori Numata, Katsutoshi Nakayama, Hirofumi Utsumi, Kenji Kobayashi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Kazuyoshi Kuwano
Publikováno v:
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-9 (2019)
Abstract Background Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid main
Externí odkaz:
https://doaj.org/article/15a0fc23ace545159587a6dcd813756e
Autor:
Masaomi Kubota, Nobumasa Tamura, Takaaki Hayashi, Euido Nishijima, Haruhiko Yanagisawa, Akira Kojima, Tadashi Nakano
Publikováno v:
Case Reports in Ophthalmological Medicine, Vol 2021 (2021)
Treatments for paraneoplastic optic neuropathy (PON), a tumor-related autoimmune disease, include immunosuppression, plasma exchange, and immunoglobulin therapies, as well as treatment of the underlying disease. Herein, we describe the clinical cours
Externí odkaz:
https://doaj.org/article/94436c52c0fe4419828426c287053812
Autor:
Takanori Numata, Katsutoshi Nakayama, Satoko Fujii, Yoko Yumino, Nayuta Saito, Masahiro Yoshida, Yusuke Kurita, Kenji Kobayashi, Saburo Ito, Hirofumi Utsumi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Hiroshi Wakui, Shunsuke Minagawa, Takeo Ishikawa, Hiromichi Hara, Jun Araya, Yumi Kaneko, Kazuyoshi Kuwano
Publikováno v:
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-8 (2018)
Abstract Background Postoperative pulmonary complications (PPC) in patients with pulmonary diseases remain to be resolved clinical issue. However, most evidence regarding PPC has been established more than 10 years ago. Therefore, it is necessary to
Externí odkaz:
https://doaj.org/article/d3b90ddb33734d108fc053a57367d64e
Autor:
Yusuke Kurita, Jun Araya, Shunsuke Minagawa, Hiromichi Hara, Akihiro Ichikawa, Nayuta Saito, Tsukasa Kadota, Kazuya Tsubouchi, Nahoko Sato, Masahiro Yoshida, Kenji Kobayashi, Saburo Ito, Yu Fujita, Hirofumi Utsumi, Haruhiko Yanagisawa, Mitsuo Hashimoto, Hiroshi Wakui, Yutaka Yoshii, Takeo Ishikawa, Takanori Numata, Yumi Kaneko, Hisatoshi Asano, Makoto Yamashita, Makoto Odaka, Toshiaki Morikawa, Katsutoshi Nakayama, Kazuyoshi Kuwano
Publikováno v:
Respiratory Research, Vol 18, Iss 1, Pp 1-14 (2017)
Abstract Background Pirfenidone (PFD) is an anti-fibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), but its precise mechanism of action remains elusive. Accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remod
Externí odkaz:
https://doaj.org/article/1146926490a44a5c8c9022cb1d7ba748
Autor:
Euido Nishijima, Takaaki Hayashi, Masaomi Kubota, Akira Kojima, Nobumasa Tamura, Tadashi Nakano, Haruhiko Yanagisawa
Publikováno v:
Case Reports in Ophthalmological Medicine
Case Reports in Ophthalmological Medicine, Vol 2021 (2021)
Case Reports in Ophthalmological Medicine, Vol 2021 (2021)
Treatments for paraneoplastic optic neuropathy (PON), a tumor-related autoimmune disease, include immunosuppression, plasma exchange, and immunoglobulin therapies, as well as treatment of the underlying disease. Herein, we describe the clinical cours
Autor:
Satoko Fujii, Jun Araya, Kenji Kobayashi, Masahiro Yoshida, Takeo Ishikawa, Hirofumi Utsumi, Katsutoshi Nakayama, Hiromichi Hara, Nayuta Saito, Yusuke Kurita, Mitsuo Hashimoto, Shunsuke Minagawa, Haruhiko Yanagisawa, Yumi Kaneko, Takanori Numata, Kazuyoshi Kuwano, Hiroshi Wakui, Yoko Yumino, Saburo Ito
Publikováno v:
BMC Pulmonary Medicine, Vol 18, Iss 1, Pp 1-8 (2018)
BMC Pulmonary Medicine
BMC Pulmonary Medicine
Background Postoperative pulmonary complications (PPC) in patients with pulmonary diseases remain to be resolved clinical issue. However, most evidence regarding PPC has been established more than 10 years ago. Therefore, it is necessary to evaluate
Autor:
Tsukasa Kadota, Nahoko Sato, Kenji Kobayashi, Hiroshi Wakui, Toshiaki Morikawa, Yoichi Nakanishi, Makoto Yamashita, Takeo Ishikawa, Hirofumi Utsumi, Kazuyoshi Kuwano, Yu Fujita, Makoto Odaka, Yumi Kaneko, Saburo Ito, Mitsuo Hashimoto, Katsutoshi Nakayama, Kazuya Tsubouchi, Haruhiko Yanagisawa, Jun Araya, Hisatoshi Asano, Shunsuke Minagawa, Hiromichi Hara, Yusuke Kurita, Masahiro Yoshida, Yutaka Yoshii, Nayuta Saito, Takanori Numata, Akihiro Ichikawa
Publikováno v:
Autophagy. 13:1420-1434
Accumulation of profibrotic myofibroblasts is involved in the process of fibrosis development during idiopathic pulmonary fibrosis (IPF) pathogenesis. TGFB (transforming growth factor β) is one of the major profibrotic cytokines for myofibroblast di
Autor:
Hirofumi Utsumi, Jun Kojima, Mitsuo Hashimoto, Haruhiko Yanagisawa, Kenji Kobayashi, Yu Fujita, Yusuke Kurita, Kenichiro Shimizu, Naoki Takasaka, Jun Araya, Masahiro Yoshida, Hisatoshi Asano, Makoto Yamashita, Makoto Odaka, Kazuya Tsubouchi, Nahoko Sato, Nayuta Saito, Makoto Kawaishi, Shunsuke Minagawa, Takanori Numata, Hiroshi Wakui, Katsutoshi Nakayama, Saburo Ito, Yumi Kaneko, Tsukasa Kadota, Hiromichi Hara, Kazuyoshi Kuwano, Toshiaki Morikawa
Publikováno v:
The Journal of Immunology. 197:504-516
Fibroblastic foci, known to be the leading edge of fibrosis development in idiopathic pulmonary fibrosis (IPF), are composed of fibrogenic myofibroblasts. Autophagy has been implicated in the regulation of myofibroblast differentiation. Insufficient
Autor:
Masahiro Yoshida, Tsukasa Kadota, Katsutoshi Nakayama, Yusuke Kurita, Akihiro Ichikawa, Saburo Ito, Kazuyoshi Kuwano, Yumi Kaneko, Jun Araya, Hiromichi Hara, Kenji Kobayashi, Shunsuke Minagawa, Nayuta Saito, Takeo Ishikawa, Hirofumi Utsumi, Mitsuo Hashimoto, Haruhiko Yanagisawa, Yusuke Hosaka, Hiroshi Wakui, Takanori Numata, Kazuya Tsubouchi
Publikováno v:
Airway Cell Biology and Immunopathology.
Autor:
Takanori Numata, Takeo Ishikawa, Hirofumi Utsumi, Hiromichi Hara, Kenji Kobayashi, Mitsuo Hashimoto, Haruhiko Yanagisawa, Jun Araya, Kazuyoshi Kuwano, Katsutoshi Nakayama, Shunsuke Minagawa
Publikováno v:
BMC Pulmonary Medicine
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-9 (2019)
BMC Pulmonary Medicine, Vol 19, Iss 1, Pp 1-9 (2019)
Background Several major randomized control studies have demonstrated that mepolizumab, an anti-IL-5 monoclonal antibody, is effective for patients with severe eosinophilic asthma who show exacerbation or require systemic corticosteroid maintenance t